These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12704411)

  • 1. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction.
    Johnson KJ; Peng KW; Allen C; Russell SJ; Galanis E
    Gene Ther; 2003 May; 10(9):725-32. PubMed ID: 12704411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
    Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E
    J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of specificity of cell-surface protease targeting of a cytotoxic hyperfusogenic gibbon ape leukaemia virus envelope glycoprotein.
    Kirkham LA; Bateman AR; Melcher AA; Vile RG; Fielding AK
    J Gene Med; 2002; 4(6):592-600. PubMed ID: 12439851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein.
    Zhang J; Frolov I; Russell SJ
    J Gene Med; 2004 Oct; 6(10):1082-91. PubMed ID: 15368589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
    Galanis E; Bateman A; Johnson K; Diaz RM; James CD; Vile R; Russell SJ
    Hum Gene Ther; 2001 May; 12(7):811-21. PubMed ID: 11339897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy.
    Higuchi H; Bronk SF; Bateman A; Harrington K; Vile RG; Gores GJ
    Cancer Res; 2000 Nov; 60(22):6396-402. PubMed ID: 11103804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display.
    Fielding AK; Chapel-Fernandes S; Chadwick MP; Bullough FJ; Cosset FL; Russell SJ
    Hum Gene Ther; 2000 Apr; 11(6):817-26. PubMed ID: 10779159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy.
    Diaz RM; Bateman A; Emiliusen L; Fielding A; Trono D; Russell SJ; Vile RG
    Gene Ther; 2000 Oct; 7(19):1656-63. PubMed ID: 11083474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fusogenic membrane glycoproteins induce syncytia formation and death in vitro and in vivo: a potential therapy agent for lung cancer.
    Lin EH; Salon C; Brambilla E; Lavillette D; Szecsi J; Cosset FL; Coll JL
    Cancer Gene Ther; 2010 Apr; 17(4):256-65. PubMed ID: 19893593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of NF-kappaB in fusogenic membrane glycoprotein causing HL-60 cell death: implications for acute myeloid leukemia.
    Tan L; Jia H; Liu R; Wu J; Han H; Zuo Y; Yang S; Huang W
    Cancer Lett; 2009 Jan; 273(1):114-21. PubMed ID: 18783878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The construction of recombinant type I herpes simplex virus carrying GALV.fus gene and its antitumor effect in nude mice].
    Zhu M; Yang JR; Jiang YQ; Chen SF; Fu XP; Tian ZD
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 42(2):152-6. PubMed ID: 21500543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy.
    Errington F; Bateman A; Kottke T; Thompson J; Harrington K; Merrick A; Hatfield P; Selby P; Vile R; Melcher A
    Clin Cancer Res; 2006 Feb; 12(4):1333-41. PubMed ID: 16489091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
    Simpson GR; Han Z; Liu B; Wang Y; Campbell G; Coffin RS
    Cancer Res; 2006 May; 66(9):4835-42. PubMed ID: 16651439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testican 2 abrogates inhibition of membrane-type matrix metalloproteinases by other testican family proteins.
    Nakada M; Miyamori H; Yamashita J; Sato H
    Cancer Res; 2003 Jun; 63(12):3364-9. PubMed ID: 12810672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
    Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E
    Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.
    Kaliberov S; Stackhouse MA; Kaliberova L; Zhou T; Buchsbaum DJ
    Gene Ther; 2004 Apr; 11(8):658-67. PubMed ID: 14973547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth.
    Bateman A; Bullough F; Murphy S; Emiliusen L; Lavillette D; Cosset FL; Cattaneo R; Russell SJ; Vile RG
    Cancer Res; 2000 Mar; 60(6):1492-7. PubMed ID: 10749110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
    Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
    Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Envelope fusion protein binding studies in an inducible model of retrovirus receptor expression and in CD34(+) cells emphasize limited transduction at low receptor levels.
    Kurre P; Morris J; Miller AD; Kiem HP
    Gene Ther; 2001 Apr; 8(8):593-9. PubMed ID: 11320405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1.
    Stitz J; Buchholz CJ; Engelstädter M; Uckert W; Bloemer U; Schmitt I; Cichutek K
    Virology; 2000 Jul; 273(1):16-20. PubMed ID: 10891403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.